Clinic Roundup

Profectus BioSciences Inc., of Baltimore, and the HIV Vaccine Trials Network started a Phase I HIV vaccine study involving a recombinant vesicular stomatitis virus that expresses the HIV-1 gag protein. Sixty HIV-uninfected adults will be enrolled, and the trial will evaluate safety and immunogenicity of increasing doses of the vaccine. The study is being sponsored by the National Institute of Allergy and Infectious Diseases.